why choose us

First received: December 06, 2022

Clinical Trial: Stereotactic Ablative Radiation Therapy for Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Sparing the Urethra, Pudendal Artery and Rectum During Stereotactic Ablative Body Radiotherapy (SUPR-SABR) for Low and Intermediate Risk Prostate Cancer

Brief Summary: This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer.Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of the rectum and pudendal arteries (SUPR-SABR).This study tests the hypothesis that genitourinary (GU) and gastrointestinal (GI) toxicity rates following SUPR-SABR are comparable to (or possibly lower than) historical GU and GI toxicity rates following standard SABR (stSABR) with 36.25 Gy in…

Read more